Chapman Marcus 4
4 · Seres Therapeutics, Inc. · Filed Nov 25, 2019
Insider Transaction Report
Form 4
Chapman Marcus
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2019-11-01+12,000→ 12,000 total - Exercise/Conversion
Restricted Stock Units
2019-11-01−12,000→ 0 total→ Common Stock (12,000 underlying) - Sale
Common Stock
2019-11-22$3.91/sh−3,400$13,297→ 8,600 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, dated June 15, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.93. The reporting person undertakes to provide Seres Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F4]The restricted stock units vested in full on November 1, 2019.